Editing HOT-17

'''HOT-17''' is a [[psychedelic drug]] and a member of the [[phenethylamine]] family. It is related to the more well-known compounds [[2C-E]] and [[DOB]]. HOT-17 was first synthesized and studied by the team led by [[Alexander Shulgin]].

==Chemistry==
HOT-17, or 2,5-dimethoxy-4-(β-[[isohexyl]])-phenethylamine, is a [[substituted phenethylamine]] featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. HOT-17 shares this phenethylamine structure with other psychedelic drugs like [[mescaline]] and [[2C-B]].

==Pharmacology==
The pharmacological mechanisms of HOT-17 are not well understood. It is believed to act as a [[5-HT2A receptor]] agonist, similar to other psychedelic phenethylamines. However, the exact nature of its interactions with the 5-HT2A receptor and other potential targets is not known.

==Effects==
The effects of HOT-17 are largely unknown due to the lack of scientific research. Anecdotal reports suggest that it produces effects similar to other psychedelic phenethylamines, including open and closed-eye visuals, time distortion, enhanced introspection, and altered auditory and visual perception.

==Legality==
The legality of HOT-17 varies by country. In the United States, it is not specifically listed as a controlled substance, but it could potentially be considered an analog of DOB, which is a Schedule I drug under the [[Controlled Substances Act]].

==See also==
* [[Phenethylamine]]
* [[Psychedelic drug]]
* [[Alexander Shulgin]]
* [[DOB]]
* [[2C-E]]

[[Category:Psychedelic phenethylamines]]
[[Category:Designer drugs]]
[[Category:Substituted phenethylamines]]
{{Psychoactive-stub}}
<gallery>
File:HOT-17.png|HOT-17
</gallery>